Bossard Holding Ord Shs BHAGF

Industrials Business Equipment

Bossard Holding AG is a Switzerland-based holding company of the Bossard Group specialized in the procurement and sale of fastening elements. Through its operating entities, the Company focuses on the procurements of fasteners, including sales, technical and engineering support and inventory management. The Company’s business model covers three strategic areas: Product Solutions, providing product line, which covers standard parts, components developed in-house, branded products, as well as special parts; Application Engineering, which includes technical advice, and Customer Logistics, which offers logistic solutions. The Company has approximately 50 locations worldwide. The Company’s products include Bossard ecosyn, screws and fastening elements, standard fasteners, custom-made screws, nut and bolts for special uses and brand-name fasteners. The Company operates through its subsidiaries in Europe, America and Aisia.

PINL:BHAGF - Post by User

Bossard Holding Ord Shs > SEEL...2nd RS in just over 6 months......shave & a haircut !

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon May 24, 2024 12:36pm

39 Views

Post# 36056118

RE:SEEL...2nd RS in just over 6 months......shave & a haircut !

Iseneschal wrote:

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split

2024-05-14 08:45 ET - News Release

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split

PR Newswire

NEW YORK, May 14, 2024

NEW YORK, May 14, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-8 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Thursday, May 16, 2024.

Then 2 days after the RS they do a P.O at $2.46....here is the NR :

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

2024-05-16 20:45 ET - News Release

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

PR Newswire

NEW YORK, May 16, 2024

NEW YORK, May 16, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 380,968 shares of common stock and pre-funded warrants to purchase up to 81,239 shares of common stock at a price of $2.46 per share (or $2.459 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $1.1 million, before deducting the placement agent's fees and other estimated offering expenses.